Assura PLC’s (AGR) Buy Rating Reiterated at Liberum Capital
Liberum Capital reaffirmed their buy rating on shares of Assura PLC (LON:AGR) in a research report released on Monday morning. They currently have a GBX 68 ($0.90) price objective on the real estate investment trust’s stock.
Separately, Peel Hunt reiterated a hold rating and set a GBX 55 ($0.73) target price on shares of Assura PLC in a report on Tuesday, June 20th.
Assura PLC (AGR) opened at 62.85 on Monday. Assura PLC has a 12 month low of GBX 51.35 and a 12 month high of GBX 67.30. The firm’s market capitalization is GBX 1.04 billion. The stock’s 50 day moving average price is GBX 64.05 and its 200-day moving average price is GBX 62.25.
The firm also recently disclosed a dividend, which will be paid on Wednesday, October 18th. Shareholders of record on Thursday, September 14th will be paid a dividend of GBX 0.60 ($0.01) per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a yield of 0.91%.
Assura PLC Company Profile
Assura plc is a United Kingdom-based healthcare real estate investment trust (REIT). The Company is a primary care property investor and developer. The Company develops, invests and manages a portfolio of primary care medical centers across the United Kingdom. The Company’s property portfolio includes Alwoodley Medical Centre, Leeds; Fleetwood Health and Wellbeing Centre, Fleetwood; Frome Medical Practice, Frome; Claremont Medical Centre, Surbiton; Elbury Moor Medical Centre; Grey Gable Surgery; Trellech Surgery; Bewdley Medical Centre; Malmesbury Primary Care Centre, Malmesbury, and Urmston Group Practice, Urmston.
Receive News & Stock Ratings for Assura PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assura PLC and related stocks with our FREE daily email newsletter.